Key result
Novel RNA, viral, and CRISPR gene therapies emerge to treat lipid disorders.
Why the study?
Current lipid-lowering treatments fail to help all patients reach guideline-recommended cholesterol levels, and some lipid disorders lack therapeutic options beyond dietary restriction.
Design
Review
Authors
Loading...
Novel genetic insights into lipid disorders may inform targeted therapies; leaves open clinical translation pending prospective validation.
This review highlights the development of novel gene expression and epigenetic targeting therapies for lipid disorders to address unmet clinical needs.
Tirronen et al. (2019) conducted a review in Lipid disorders. Novel lipid-lowering therapies was evaluated. Novel lipid-lowering therapies utilizing targeted RNA technology, viral gene therapy, and CRISPR/Cas gene editing are being developed to address unmet needs in treating lipid disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: